Website
News25/Ratings12
Price$9.29+0.69 (+8.02%)
2026-01-202026-04-23
News · 26 weeks62-14%
2025-10-262026-04-19
Mix2490d
- Insider8(33%)
- Other6(25%)
- SEC Filings5(21%)
- Earnings4(17%)
- Analyst1(4%)
Latest news
25 items- PRKura Oncology Reports Darlifarnib Plus Cabozantinib Demonstrates Robust Activity in Patients With Clear Cell Renal Cell Carcinoma Previously Treated With CabozantinibData from subset analysis of cabozantinib-pretreated patients support potential to overcome resistance and resensitize tumors to VEGF TKI therapy 44% ORR and 94% DCR in ccRCC patients previously treated with cabozantinib, with tumor shrinkage observed in 75% of patients Responses observed in heavily pretreated patients, including those with stable disease on prior cabozantinib Durable treatment durations reaching 56 weeks, with one-third of patients remaining on therapy at time of data cut-off Manageable safety and tolerability profile in all RCC patients across multiple dose levels Virtual investor event today, April 17, 2026, at 7:30 a.m. PT / 10:30 a.m. ET / 4:30 p.m. CEST SAN DIEG
- ANALYSTLake Street initiated coverage on Kura Oncology with a new price targetLake Street initiated coverage of Kura Oncology with a rating of Buy and set a new price target of $23.00
- SECSEC Form DEFA14A filed by Kura Oncology Inc.DEFA14A - Kura Oncology, Inc. (0001422143) (Filer)
- SECSEC Form DEF 14A filed by Kura Oncology Inc.DEF 14A - Kura Oncology, Inc. (0001422143) (Filer)
- PRKura Oncology to Present Darlifarnib Plus Cabozantinib Data in Patients with Clear Cell Renal Cell Carcinoma Previously Treated with Cabozantinib at IKCS Europe 2026Data build on findings presented at ESMO 2025 and support potential of darlifarnib to overcome resistance and resensitize tumors to VEGFR TKI therapy Virtual investor call on April 17, 2026, at 7:30 a.m. PT / 10:30 a.m. ET / 4:30 p.m. CEST SAN DIEGO, April 09, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a biopharmaceutical company focused on precision medicines for the treatment of cancer, today announced it will present updated data from its ongoing FIT-001 clinical trial (NCT 06026410) evaluating darlifarnib (KO-2806) in combination with cabozantinib in patients with advanced clear cell renal cell carcinoma at the International Kidney Cancer Symposium (IKCS) Europe 2026
- PRKura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)SAN DIEGO, April 03, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the "Company") (NASDAQ:KURA), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that on April 1, 2026, the Compensation Committee of the Company's Board of Directors (the "Compensation Committee") granted inducement awards consisting of nonstatutory stock options to purchase 153,750 shares of common stock to six (6) new employees under the Company's 2023 Inducement Option Plan, as amended. The Compensation Committee approved the stock options as an inducement material to such employees' employment in accordance with Nasdaq Listing Rule 5635(c)(
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Kura Oncology Inc.SCHEDULE 13G/A - Kura Oncology, Inc. (0001422143) (Subject)
- INSIDERSEC Form 4 filed by Wilson Troy Edward4 - Kura Oncology, Inc. (0001422143) (Issuer)
- INSIDERSEC Form 4 filed by Malley Thomas4 - Kura Oncology, Inc. (0001422143) (Issuer)
- PRKura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)SAN DIEGO, March 06, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the "Company") (NASDAQ:KURA), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that on March 2, 2026, the Compensation Committee of the Company's Board of Directors (the "Compensation Committee") granted inducement awards consisting of nonstatutory stock options to purchase 44,700 shares of common stock to four (4) new employees under the Company's 2023 Inducement Option Plan, as amended. The Compensation Committee approved the stock options as an inducement material to such employees' employment in accordance with Nasdaq Listing Rule 5635(c)(
- SECSEC Form 10-K filed by Kura Oncology Inc.10-K - Kura Oncology, Inc. (0001422143) (Filer)
- SECKura Oncology Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Kura Oncology, Inc. (0001422143) (Filer)
- PRKura Oncology Reports Fourth Quarter and Full Year 2025 Financial Results– KOMZIFTI™ (ziftomenib) launch generating early revenue momentum and rapid payer coverage decisions – – Market feedback emphasizes differentiated safety, combinability and convenience of ziftomenib, supporting ongoing development plans targeting up to 50% of AML patients – – Orange Book listing of patents extending up to 2044 reinforces long-term value for KOMZIFTI – – FIT-001 Phase 1b dose expansion initiated for darlifarnib and cabozantinib combination in advanced renal cell carcinoma – – Multiple 2026 clinical data milestones expected across AML and solid tumor programs – – Strong capital position of $667.2 million in cash, cash equivalents and short-term investments, together with
- PRKura Oncology to Report Fourth Quarter and Full Year 2025 Financial ResultsSAN DIEGO, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced it will report fourth quarter and full year 2025 financial results on Thursday, March 5, 2026, before the U.S. financial markets open. Kura's management will host a conference call and webcast at 8:00 a.m. ET / 5:00 a.m. PT to discuss the financial results and provide a corporate update. The live webcast and archived replay of the event may be accessed on the Investors section of the Company's website at www.kuraoncology.com. About Kura Oncology Kura Oncology is a biopharmaceuti
- PRKura Oncology to Participate in Three Upcoming Investor ConferencesSAN DIEGO, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its participation in the following investor conferences: TD Cowen Health Care Conference March 4, 202611:50 a.m. ET / 8:50 a.m. PT Leerink Partners Global Biopharma Conference March 10, 202610:40 a.m. ET / 7:40 a.m. PT Barclays Global Healthcare Conference March 12, 20269:00 a.m. ET / 6:00 a.m. PT Live audio webcasts will be available in the Investors section of Kura's website at https://kuraoncology.com/, with archived replays available following all three events. About Kura O
- SECSEC Form SCHEDULE 13G filed by Kura Oncology Inc.SCHEDULE 13G - Kura Oncology, Inc. (0001422143) (Subject)
- PRKura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)SAN DIEGO, Feb. 06, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the "Company") (NASDAQ:KURA), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that on February 2, 2026, the Compensation Committee of the Company's Board of Directors (the "Compensation Committee") granted inducement awards consisting of nonstatutory stock options to purchase 69,750 shares of common stock to four (4) new employees under the Company's 2023 Inducement Option Plan, as amended. The Compensation Committee approved the stock options as an inducement material to such employees' employment in accordance with Nasdaq Listing Rule 5635(c
- SECSEC Form 8-K filed by Kura Oncology Inc.8-K - Kura Oncology, Inc. (0001422143) (Filer)
- INSIDERChief Legal Officer Bair Teresa Brophy sold $94,828 worth of shares (11,208 units at $8.46), decreasing direct ownership by 5% to 226,931 units (SEC Form 4)4 - Kura Oncology, Inc. (0001422143) (Issuer)
- INSIDERChief Commercial Officer Powl Brian T. sold $54,266 worth of shares (6,414 units at $8.46), decreasing direct ownership by 3% to 183,275 units (SEC Form 4)4 - Kura Oncology, Inc. (0001422143) (Issuer)
- INSIDERChief Scientific Officer Burrows Francis sold $11,092 worth of shares (1,311 units at $8.46), decreasing direct ownership by 4% to 32,424 units (SEC Form 4)4 - Kura Oncology, Inc. (0001422143) (Issuer)
- INSIDERChief Operating Officer Ford Kathleen sold $15,339 worth of shares (1,813 units at $8.46), decreasing direct ownership by 1% to 153,560 units (SEC Form 4)4 - Kura Oncology, Inc. (0001422143) (Issuer)
- INSIDERSVP, Finance & Accounting Doyle Thomas James sold $60,426 worth of shares (7,142 units at $8.46), decreasing direct ownership by 5% to 145,167 units (SEC Form 4)4 - Kura Oncology, Inc. (0001422143) (Issuer)
- INSIDERChief Medical Officer Leoni Mollie sold $69,209 worth of shares (8,180 units at $8.46), decreasing direct ownership by 3% to 267,274 units (SEC Form 4)4 - Kura Oncology, Inc. (0001422143) (Issuer)
- SECKura Oncology Inc. filed SEC Form 8-K: Results of Operations and Financial Condition8-K - Kura Oncology, Inc. (0001422143) (Filer)